Capital Increase / Dilution2026-07-16

CB Issuance Details Amended, Dilution Risk Up

LCB

리가켐바이오

141080

-0.65

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2571

Risk-adjusted indicator based on 2571 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEGATIVE

Key Numbers

  • • Total CB Issuance: 170B KRW
  • • Amended Conversion Price: 121,400 KRW/Share (down from 149,300 KRW/Share)
  • • Amended Convertible Shares: 1,400,329 Shares (up from 1,138,647 Shares)
  • • Amended Dilution Rate: 3.78% (up from 3.08%)
  • • Lowest Adjustment Price: 97,200 KRW

AI Analysis Summary

LigaChem Biosciences Inc. has amended its Material Fact Report regarding the issuance of convertible bonds (CBs). The total CB issuance remains 170B KRW, but the conversion price has been adjusted downwards from 149,300 KRW/Share to 121,400 KRW/Share. This change increases the number of convertible shares from 1,138,647 to 1,400,329, leading to a higher potential dilution rate for existing shareholders, now at 3.78% (previously 3.08%). The lowest adjustment price for the conversion is set at 97,200 KRW. This amendment indicates increased potential dilution, which is generally negative for existing shareholders.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(전환사채권발행결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.